Key Drivers
- Strong liquidity
- Rising leverage
- Weak quarter
AIAI Summary
ARWR has shifted from a pure science-optionality story to a late-stage validation-and-commercialization test case, where the main upside is plozasiran/REDEMPLO adoption but the key risk is that weak payer coverage, rising debt, and negative operating leverage could prevent clinical success from turning into durable revenue.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Rising leverage
- •Weak quarter
ARWR ended FY2025 with solid profitability and free cash flow, but the latest quarter showed a sharp revenue drop, heavy operating losses, and rising leverage despite a strong liquidity cushion.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Support holding
- •Near resistance
ARWR has trended higher over the last month with orderly pullbacks holding the mid-$85s, but it needs a clean breakout above $89.5-$90 to confirm the bullish move.
Sharp jump on 2026-07-22 followed by a peak near $89.59 on 2026-08-04
Sentiment & News
Key News Insights:
- •Phase 3 Success
- •NDA Acceleration
- •Institutional Accumulation
Arrowhead delivered strong late-stage clinical wins for plozasiran and zodasiran, accelerating regulatory plans while attracting fresh institutional buying and supporting continued momentum in the stock.
The news is bullish for Arrowhead, as positive clinical readouts and a near-term regulatory filing catalyst could support valuation and investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings